Shanghai Junshi Bioscience Co., Ltd.: Neoplasms trials
The registry lists 10 Neoplasms studies with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor. 0 are open to participants now and 0 have results posted.
Phase 1 10(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced MalignanciesWithdrawnNCT05650203Phase 1
- A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid TumorsTerminatedNCT05388279Phase 1
- JS001+IMP4297 in Patients With Advanced CancerWithdrawnNCT05262842Phase 1
- A Clinical Study of TAB006 in Patients With Previously Treated, Advanced MalignanciesWithdrawnNCT05253105Phase 1
- A Study Explore JS001+JS002 in Patients With Advanced CancerTerminatedNCT05128539Phase 1
- Clinical Study of JS007 in Patients With Advanced Solid TumorsStatus unknownNCT05049265Phase 1
- Clinical Study of JS201 in Patients With Advanced Malignant TumorsStatus unknownNCT04956926Phase 1
- A Phase I Study of JS108 in Patients With Advanced Solid TumorsTerminatedNCT04601285Phase 1
- Safety, Tolerability and Pharmacokinetics of a Recombinant Humanized mAb Specific to B-and T-Lymphocyte Attenuator (BTLA) for Injection in Subjects With Advanced MalignanciesCompletedNCT04278859Phase 1
- Study of JS001 in Participants With Advanced Solid TumorsCompletedNCT02857166Phase 1